➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
Harvard Business School
Dow
Johnson and Johnson

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

HUMIRA Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for HUMIRA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Shandong Qilu Stem Cells Engineering Co., Ltd.N/A
Chemical, Biological, Radiological, and Nuclear MedicalPhase 3
Pharm-Olam, LLCPhase 3

See all HUMIRA clinical trials

Recent Litigation for HUMIRA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Pharmacyclics LLC v. Alvogen Pine Brook, LLC2020-03-20
Coherus Biosciences, Inc. v. Amgen Inc.2019-01-23
ABBVIE INC. v. SANDOZ INC.2018-08-10

See all HUMIRA litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
2017-12-20
Sandoz Inc.2017-11-06

See all HUMIRA litigation

Pharmacology for HUMIRA

Patent Text Search: US Patents for HUMIRA

These patents were identified by searching patent claims

Supplementary Protection Certificates for HUMIRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2090010-6 Sweden   Get Started Free PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1404 20191218
132016000070123 Italy   Get Started Free PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
300911 Netherlands   Get Started Free PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
122016000049 Germany   Get Started Free PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
PA2017009 Lithuania   Get Started Free PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKesson
Boehringer Ingelheim
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.